Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jing Su

Showing results (1461-1470 of 1,472) with videos related to

Pageof 148
Sort By:
ACS Medicinal Chemistry Letters|May 20, 2026
Discovery of Potent 1,3-Cyclobutane-Containing Dual A<sub>2A</sub>/A<sub>2B</sub> Receptor Antagonists with Low Projected Human Dose for the Treatment of CancerZachary G Brill, Alec H Christian, Lorena Rico, et al.
Signal Transduction and Targeted Therapy|February 2, 2026
Wnt-associated DKK3 in keratinocytes mediates radiation-induced hyperplasia, dermatitis and skin fibrosisLi Li, Ramon Lopez Perez, Khuram Shehzad, et al.
ACS Infectious Diseases|April 6, 2024
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential LiabilitiesHelena I M Boshoff, Katherine Young, Yong-Mo Ahn, et al.
Journal of Medicinal Chemistry|March 22, 2017
Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO InhibitorMihirbaran Mandal, Zheng Tan, Christina Madsen-Duggan, et al.
Nature Medicine|January 13, 2026
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosisBrendan M Crowley, Helena I Boshoff, Aidan Boving, et al.
Journal of Medicinal Chemistry|September 4, 2024
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 InhibitorsKaitlyn M Logan, Will Kaplan, Vladimir Simov, et al.
Journal of Medicinal Chemistry|December 30, 2021
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 InhibitorsMitchell H Keylor, Anmol Gulati, Solomon D Kattar, et al.
Journal of Medicinal Chemistry|December 8, 2022
Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical CandidatesMihirbaran Mandal, Li Xiao, Weidong Pan, et al.
Journal of Medicinal Chemistry|February 22, 2024
Structure Guided Discovery of Novel Pan Metallo-β-Lactamase Inhibitors with Improved Gram-Negative Bacterial Cell PenetrationShuzhi Dong, Zhiqiang Zhao, Haiqun Tang, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Pageof 148

Showing results (1461-1470 of 1,472) with videos related to

Sort By:
Pageof 148
ACS Medicinal Chemistry Letters|May 20, 2026
Discovery of Potent 1,3-Cyclobutane-Containing Dual A<sub>2A</sub>/A<sub>2B</sub> Receptor Antagonists with Low Projected Human Dose for the Treatment of CancerZachary G Brill, Alec H Christian, Lorena Rico, et al.
Signal Transduction and Targeted Therapy|February 2, 2026
Wnt-associated DKK3 in keratinocytes mediates radiation-induced hyperplasia, dermatitis and skin fibrosisLi Li, Ramon Lopez Perez, Khuram Shehzad, et al.
ACS Infectious Diseases|April 6, 2024
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential LiabilitiesHelena I M Boshoff, Katherine Young, Yong-Mo Ahn, et al.
Journal of Medicinal Chemistry|March 22, 2017
Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO InhibitorMihirbaran Mandal, Zheng Tan, Christina Madsen-Duggan, et al.
Nature Medicine|January 13, 2026
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosisBrendan M Crowley, Helena I Boshoff, Aidan Boving, et al.
Journal of Medicinal Chemistry|September 4, 2024
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 InhibitorsKaitlyn M Logan, Will Kaplan, Vladimir Simov, et al.
Journal of Medicinal Chemistry|December 30, 2021
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 InhibitorsMitchell H Keylor, Anmol Gulati, Solomon D Kattar, et al.
Journal of Medicinal Chemistry|December 8, 2022
Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical CandidatesMihirbaran Mandal, Li Xiao, Weidong Pan, et al.
Journal of Medicinal Chemistry|February 22, 2024
Structure Guided Discovery of Novel Pan Metallo-β-Lactamase Inhibitors with Improved Gram-Negative Bacterial Cell PenetrationShuzhi Dong, Zhiqiang Zhao, Haiqun Tang, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Pageof 148